Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Cencora (COR) Raised Guidance and Bought Back $1B. Whatโ€™s the Catch?

AI-generated analysis

๐Ÿ“ˆ Cencora raised full-year adjusted EPS guidance to $17.75-$17.95 following a 12.0% year-over-year increase in adjusted earnings per share to $4.48.

๐Ÿ’ฐ The company accelerated its capital return strategy by completing a $1 billion stock buyback in the quarter, ahead of its original calendar-year target.

๐Ÿ“Š Adjusted operating income surged 17.0% while revenue grew 5.1%, driven by a 23.2% increase in gross profit and a margin expansion to 4.16%.

๐Ÿฅ The OneOncology acquisition contributed significantly to US business growth, lifting margins but also adding substantial operating expenses and debt financing costs.

โš ๏ธ Operating expenses jumped 26.8%, outpacing gross profit growth, as the company integrates higher-cost oncology operations into its existing business model.

๐Ÿ“‰ Net interest expense rose $58.9 million year-over-year due to new senior notes and variable-rate term loans used to fund acquisitions.

๐Ÿงฌ Lower-margin GLP-1 drug sales for diabetes and weight loss are diluting overall profitability as these products add revenue but less profit per dollar.

๐Ÿ“‰ Cencora lost a major oncology customer in 2025, which negatively impacted US revenue alongside lower sales to a large mail-order pharmaceutical customer.

๐Ÿฆ Hedge fund ownership increased slightly to 63 funds from 61, indicating modest institutional interest despite the stock trading at 15.55 times forward earnings.

๐Ÿ’ธ The board declared a $0.60 quarterly dividend payable August 31 to holders of record on August 14.

Bullish Signals
  • Cencora raised its full-year adjusted EPS guidance to $17.75-$17.95, signaling management confidence in future profitability despite market headwinds.
  • The company completed a $1 billion stock buyback in a single quarter, demonstrating strong cash flow generation and a commitment to returning capital to shareholders.
  • Adjusted gross margin expanded 61 basis points to 4.16%, driven by a 23.2% increase in gross profit and successful integration of the OneOncology acquisition.
  • International Healthcare Solutions delivered robust performance with operating income up 20.8%, highlighting strength in European distribution and global specialty logistics.
  • US Healthcare Solutions grew operating income by 15.9% on higher pharmaceutical sales, validating the core business model outside of oncology.
Risk Factors
  • Operating expenses increased 26.8%, significantly outpacing gross profit growth, as the OneOncology acquisition brought substantial integration costs and overhead.
  • Net interest expense rose $58.9 million year-over-year due to new debt financing, which will weigh on bottom-line profitability in the coming quarters.
  • The sales mix is shifting toward lower-margin GLP-1 drugs for diabetes and weight loss, reducing the profit contribution per dollar of revenue generated.
  • Cencora lost a significant oncology customer in 2025, which directly impacted US revenue and offset some gains from other segments.
  • Lower manufacturer prices on certain brand pharmaceuticals are suppressing revenue growth in the domestic market.
Full Analysis
Cencora (NYSE: COR) reported a strong fiscal third quarter with revenue rising 5.1% to $84.8 billion and adjusted earnings per share climbing 12.0% to $4.48. Management raised its full-year adjusted EPS outlook to between $17.75 and $17.95, while the company accelerated its capital return program by completing a $1 billion stock buyback in a single quarter. Additionally, the board declared a quarterly dividend of $0.60. The profit growth outpaced sales growth significantly, with adjusted operating income surging 17.0% versus 5.1% revenue growth. This margin expansion was driven largely by a 23.2% jump in gross profit and a widening adjusted gross margin to 4.16%, aided by the OneOncology acquisition. Both US Healthcare Solutions and International Healthcare Solutions posted double-digit operating income increases, though international performance outperformed the domestic segment. However, the company faces structural headwinds including higher operating expenses rising 26.8% due to integration costs from the OneOncology deal, which now accounts for a larger share of total revenue. Financing costs have also increased with net interest expense up $58.9 million year-over-year as the company funded acquisitions with new debt. Furthermore, lower-margin GLP-1 drug sales and the loss of a significant oncology customer are creating drag on overall profitability. Analyst sentiment remains mixed regarding the sustainability of these margin gains once acquisition-related expenses normalize. While hedge fund ownership increased slightly to 63 funds, the stock trades at 15.55 times forward earnings. The company's future performance will depend on whether it can maintain its expanded margins amidst rising interest costs and a sales mix increasingly weighted toward lower-margin pharmaceutical products.